Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Grupo Yacana Mexico, S.A.S. de C.V.
WARNING LETTER
•Grupo Yacana Mexico, S.A.S. de C.V.•January 26, 2021

FDA WARNING_LETTER - Grupo Yacana Mexico, S.A.S. de C.V. - January 26, 2021

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Grupo Yacana Mexico, S.A.S. de C.V.
Record Details

The FDA issued a Warning Letter to Grupo Yacana Mexico, S.A.S. de C.V. after testing their YACANA Alcohol Antiseptic 70% and YACANA Isopropyl Alcohol Antiseptic 70% hand rub products, which were detained at the U.S. border. Laboratory analysis revealed significant adulteration and misbranding. The YACANA Alcohol Antiseptic 70% product was found to contain methanol (a toxic substance) instead of ethyl alcohol, and the YACANA Isopropyl Alcohol Antiseptic 70% product contained ethanol instead of isopropyl alcohol, and was subpotent (61% IPA instead of 70%). These findings demonstrate a failure in the firm's quality assurance system, violating CGMP requirements under 21 U.S.C. 351(a)(2)(B), 351(c), and 351(d)(2).

Furthermore, both products are considered unapproved new drugs, violating 21 U.S.C. 355(a), as they are not generally recognized as safe and effective and do not conform to applicable monographs or temporary COVID-19 policies. They are also misbranded under 21 U.S.C. 352(a), (e), (j), and (ee) due to false/misleading labeling, failure to list methanol as an ingredient, being dangerous to health, and non-compliance with nonprescription drug marketing requirements.

The FDA recommended engaging a CGMP consultant and requested detailed investigations into the substitutions, subpotency, raw materials, distribution records, and batch records. The firm had already initiated a voluntary recall, and all its products are on Import Alert 66-78, prohibiting admission without physical examination until compliance is established. A response detailing corrective actions is required within 15 working days.

Company
Grupo Yacana Mexico, S.A.S. de C.V.
Inspection Date
January 26, 2021
Product Type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Jerry Doane
Open in Dashboard

ID · 2ddf11ac-6e1d-4c14-9de0-54f98f7321ac

Violation Codes10
21 U.S.C. 351(d)(2)21 U.S.C. 351(c)21.U.S.C. 355(a)21 U.S.C. 352(a)21 U.S.C. 352(ee)21 U.S.C. 35521 U.S.C. 331(d)21 U.S.C. 321(g)(1)(B)21 U.S.C. 321(g)(1)(C)21 U.S.C. 321(p)

Full citation text and observation details available on the Dashboard.

KeyPedia
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.